Subscribe To

Price Alert Latest News Economic Calendar News

IMAB / I-Mab to Report Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022

SHANGHAI and GAITHERSBURG, MD, March 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will report financial results for the full year ended December 31, 2021 before the market opens on Tuesday, March 29, 2022, and host a conference call to discuss the results and provide a corporate update at 8:00 a.m. EST. I-Mab Conference Call Information Investors and analysts are invited to join the conference call at 8:00 a.m. Read More

Demo Live Account See Partner Details

Content Topics

Mab

Report

Full

Year

2021

Financial

Results

Provide

Corporate

Update

Stock

IMAB

Posted: Mar 18 2022, 08:00

Author Name: PRNewsWire

IMAB News

By Seeking Alpha
September 13, 2023

I-Mab: Why This Company Trades At A Third The Value Of Its Cash

Chinese biotech company I-Mab faces challenges in attracting US capital due to lack of transparency and difficulty in valuing its pipeline. I-Mab has

By Market Watch
June 27, 2023

Theft in open court: How a fight over lifesaving drugs led to charges of brazen industrial espionage

A Chinese developer of cutting-edge cancer drugs has accused a chief competitor of stealing its trade secrets by posing as an expert witness in an arb

By Seeking Alpha
August 30, 2022

I-Mab (IMAB) H1 2022 Earnings Call Transcript

I-Mab (NASDAQ:IMAB ) H1 2022 Earnings Conference Call August 30, 2022 9:15 AM ET Company Participants Tyler Ehler – Senior Director of Investor Rela

By Seeking Alpha
June 23, 2022

I-Mab Valuation Offers A Biotech Investment Opportunity

The biotech indices have fallen considerably. Many biotechs are trading with negative enterprise values despite unprecedented innovation in the biotec

By Seeking Alpha
March 29, 2022

I-Mab (IMAB) CEO Management on Q4 2021 Results - Earnings Call Transcript

By PRNewsWire
March 18, 2022

I-Mab to Report Full Year 2021 Financial Results and Provide Corporate Update on March 29, 2022

SHANGHAI and GAITHERSBURG, MD, March 18, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committ

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.